Table 1.
Baseline characteristics of study cohort.
| Median (Min-Max) | |
|---|---|
| Age | 68.00 (30.00-92.00) |
| Muscle attenuation(MA) | 30.70 (1.20-57.10) |
| IMF(intermuscular) | 5.14 (0.62-17.65) |
| TAMA | 53.87 (12.81-104.12) |
| TPA | 8.50 (2.18-42.44) |
| VFA | 58.48 (6.52-155.53) |
| SFA | 55.09 (6.27-199.02) |
| Abdominal wall fat thickness | 1.83 (0.31-4.43) |
| TPT | 2.87 (1.45-5.56) |
| APT | 3.90 (1.94-5.43) |
| LPNF | 1.68 (0.10-5.05) |
| PPNF | 1.17 (0.10-4.43) |
| PFA | 7.51 (0.21-29.30) |
| SMI | 20.63 (5.69-38.24) |
| PMI | 3.24 (0.92-13.86) |
| SFA(standardized) | 21.09 (2.30-70.51) |
| TPT(standardized) | 2.39 (0.79-2570.18) |
| APT(standardized) | 2.41 (1.21-3.28) |
| VFA/SFA | 1.05 (0.22-2.89) |
| VFA(standardized) | 22.84 (2.49-60.00) |
| (VFA+SFA+IFA)/TAMA | 2.46 (0.24-6.34) |
| VD(visceral fat density) | -96.30 (-116.10–74.30) |
| SD(subcutaneous fat density) | -102.60 (-124.40–72.70) |
| N (%) | |
| Gender | |
| Male | 148 (54.21%) |
| Female | 125 (45.79%) |
| BMI | |
| <18.5 | 29 (10.78%) |
| 18.5-23.9 | 138 (51.30%) |
| 24-26.9 | 64 (23.79%) |
| 27-29.9 | 35 (13.01%) |
| ≥29.9 | 3 (1.12%) |
| IFG(≥ 5.6)or type 2 diabetes mellitus | |
| Yes | 169 (62.83%) |
| No | 100 (37.17%) |
| Hypertension(≥130/85mmHg) | |
| No | 153 (56.04%) |
| Yes | 120 (43.96%) |
| Hydronephrosis | |
| No | 110 (41.35%) |
| Yes | 156 (58.65%) |
| Primary site | |
| Renal pelvis | 124 (45.59%) |
| Ureter | 98 (36.03%) |
| T stage | |
| Tx, Ta, Tis | 8 (2.96%) |
| T1 | 95 (35.19%) |
| T2 | 50 (18.52%) |
| T3 | 90 (33.33%) |
| T4 | 27 (10.00%) |
| Grade | |
| Low | 80 (29.74%) |
| High | 189 (70.26%) |
| Tumor size(maximum diameter) | |
| <3cm | 82 (30.37%) |
| ≥3cm | 188 (69.63%) |
| Lymph-node invasion | |
| Without | 252 (93.68%) |
| Identified | 17 (6.32%) |
| Adjuvant therapy | |
| No | 178 (77.06%) |
| Yes | 53 (22.94%) |
| Laterality | |
| Left | 145 (53.11%) |
| Right | 128 (46.89%) |
| LPNF(categorized) | |
| 0 | 86 (40.95%) |
| 1 | 82 (39.05%) |
| 2 | 42 (20.00%) |
| PPNF(categorized) | |
| 0 | 77 (36.84%) |
| 1 | 95 (45.45%) |
| 2 | 37 (17.70%) |